98 related articles for article (PubMed ID: 24324104)
21. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
[TBL] [Abstract][Full Text] [Related]
22. Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME).
Schnabel PA; Smit E; Carpeño Jde C; Leśniewski-Kmak K; Aerts J; Kraaij K; Visseren-Grul C; Dyachkova Y; Taipale K; Girvan A; Moro-Sibilot D
Lung Cancer; 2012 Dec; 78(3):263-9. PubMed ID: 23040326
[TBL] [Abstract][Full Text] [Related]
23. Induction combination chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
Herse B; Dalichau H; Wörmann B; Hemmerlein B; Schmidberger H; Hess CF; Hannemann P; Criée CP; Hiddemann W; Griesinger F
Thorac Cardiovasc Surg; 1998 Oct; 46(5):298-302. PubMed ID: 9885122
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer.
Giorgio CG; Pappalardo A; Russo A; Santini D; Di Rosa C; Di Salvo C; Castorina S; Marletta F; Bellissima G; Palermo N; Scuderi C; Bordonaro R
Anticancer Drugs; 2007 Jul; 18(6):713-9. PubMed ID: 17762402
[TBL] [Abstract][Full Text] [Related]
25. Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer.
Rice TW; Adelstein DJ; Koka A; Tefft M; Kirby TJ; Van Kirk MA; Taylor ME; Olencki TE; Peereboom D; Budd GT
Ann Thorac Surg; 1995 Sep; 60(3):586-91; discussion 591-2. PubMed ID: 7677484
[TBL] [Abstract][Full Text] [Related]
26. Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in stage III lung cancer.
Edelman MJ; Suntharalingam M; Burrows W; Kwong KF; Mitra N; Gamliel Z; Riley M; Cooper LB; Kennedy NL; Buskirk S; Hausner P; Doyle LA; Krasna MJ
Ann Thorac Surg; 2008 Sep; 86(3):903-10. PubMed ID: 18721580
[TBL] [Abstract][Full Text] [Related]
27. Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence.
Kaira K; Takahashi T; Murakami H; Shukuya T; Kenmotsu H; Naito T; Oriuchi N; Kanai Y; Endo M; Kondo H; Nakajima T; Yamamoto N
Anticancer Res; 2011 Nov; 31(11):3775-82. PubMed ID: 22110199
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of concurrent paclitaxel, carboplatin, and external-beam radiation followed by surgical resection in locally advanced non-small-cell lung cancer, protocol 99-444.
Fischer SA; Soberman M; Randolph P; Crawford K; Perry DJ
Clin Lung Cancer; 2006 Jul; 8(1):56-61. PubMed ID: 16870047
[TBL] [Abstract][Full Text] [Related]
29. Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease).
Phernambucq EC; Biesma B; Smit EF; Paul MA; vd Tol A; Schramel FM; Bolhuis RJ; Postmus PE
Br J Cancer; 2006 Aug; 95(4):470-4. PubMed ID: 16909132
[TBL] [Abstract][Full Text] [Related]
30. [Effect of pemetrexed plus platinum for chemotherapy-naive advanced non-small cell lung cancer].
Duan JC; Wu MN; Zhao J; An TT; Yang L; Bai H; Wang ZJ; Zhuo ML; Wang SH; Wang YY; Liu XH; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):97-101. PubMed ID: 22455964
[TBL] [Abstract][Full Text] [Related]
31. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.
Pourel N; Santelmo N; Naafa N; Serre A; Hilgers W; Mineur L; Molinari N; Reboul F
Eur J Cardiothorac Surg; 2008 May; 33(5):829-36. PubMed ID: 18367406
[TBL] [Abstract][Full Text] [Related]
32. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
[TBL] [Abstract][Full Text] [Related]
33. Association between certain non-small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death-ligand 1 inhibition.
Liang W; Guo M; Pan Z; Cai X; Li C; Zhao Y; Liang H; Yang H; Wang Z; Chen W; Xu C; Yang X; Sun J; He P; Gu X; Yin W; He J
Cancer Sci; 2019 Jun; 110(6):2014-2021. PubMed ID: 31033100
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients.
Jakobsen JN; Santoni-Rugiu E; Sørensen JB
Cancer Chemother Pharmacol; 2014 Jan; 73(1):43-51. PubMed ID: 24220933
[TBL] [Abstract][Full Text] [Related]
35. [The Current Immunohistochemistry Markers in the Resected Tissues of Non-small Cell Lung Cancer Could Not Predict Prognosis].
Shen L; Kang X; Sun Y; Fu H; Dai L; Yan W; Chen K
Zhongguo Fei Ai Za Zhi; 2016 Mar; 19(3):147-52. PubMed ID: 27009819
[TBL] [Abstract][Full Text] [Related]
36. PSF1 (Partner of SLD Five 1) is a Prognostic Biomarker in Patients with Non-small Cell Lung Cancer Treated with Surgery Following Preoperative Chemotherapy or Chemoradiotherapy.
Kanzaki R; Naito H; Kise K; Takara K; Eino D; Minami M; Shintani Y; Funaki S; Kawamura T; Kimura T; Okumura M; Takakura N
Ann Surg Oncol; 2016 Nov; 23(12):4093-4100. PubMed ID: 27380644
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of the mRNA expression of
Sun S; Shi W; Wu Z; Zhang G; Yang BO; Jiao S
Exp Ther Med; 2015 Sep; 10(3):937-941. PubMed ID: 26622418
[TBL] [Abstract][Full Text] [Related]
38. 8-Isoprostane in exhaled breath condensate of patients with non-small cell lung cancer: the effect of chemotherapy.
Stathopoulos D; Loukides S; Syrigos K
Anticancer Res; 2014 Sep; 34(9):5143-5. PubMed ID: 25202105
[TBL] [Abstract][Full Text] [Related]
39. Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer.
Shepherd FA; Rosell R
J Thorac Oncol; 2007 Jun; 2 Suppl 2():S68-76. PubMed ID: 17589302
[TBL] [Abstract][Full Text] [Related]
40. Differences in RRM1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in non-small-cell lung cancer.
Jakobsen JN; Santoni-Rugiu E; Sørensen JB
Histopathology; 2014 Feb; 64(3):412-20. PubMed ID: 24266856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
